ZM-8195 / Simcere - LARVOL DELTA

Discovery of a novel ALK inhibitor ZM-8195 that targets ALK compound mutations with superior TRK selectivity (AACR 2026) - "ZM-8195 was well tolerated in rodents and non-rodents. Based on its favorable activity, selectivity, pharmacokinetic profiles and safety, ZM-8195 is currently in IND enabling stage."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EML4 • NTRK2 • NTRK3